Income Statement for INM - findataslice
 InMed Pharmaceuticals Inc.
Q4-CY2025Q3-CY2025Q2-CY2025Q1-CY2025Q4-CY2024Q3-CY2024Q2-CY2024Q1-CY2024Q4-CY2023Q3-CY2023Q2-CY2023Q1-CY2023Q4-CY2022Q3-CY2022Q2-CY2022Q1-CY2022Q4-CY2021Q3-CY2021Q2-CY2021Q1-CY2021Q4-CY2020Q3-CY2020Q2-CY2020Q1-CY2020Q4-CY2019Q3-CY2019Q2-CY2019Q1-CY2019Q4-CY2018Q3-CY2018Q2-CY2018Q1-CY2018Q4-CY2017Q3-CY2017Q2-CY2017Q1-CY2017Q4-CY2016Q3-CY2016Q2-CY2016Q1-CY2016Q4-CY2015Q3-CY2015Q2-CY2015Q1-CY2015Q4-CY2014Q3-CY2014Q2-CY2014Q1-CY2014Q4-CY2013
Balance Sheet Date2025-Jun-302025-Mar-312024-Dec-312024-Sep-302024-Jun-302024-Mar-312023-Dec-312023-Sep-302023-Jun-302023-Mar-312022-Dec-312022-Sep-302022-Jun-302022-Mar-312021-Dec-312021-Sep-302021-Jun-302021-Mar-312020-Dec-312020-Sep-30
Fiscal PeriodQ4-FY2025Q3-FY2025Q2-FY2025Q1-FY2025Q4-FY2024Q3-FY2024Q2-FY2024Q1-FY2024Q4-FY2023Q3-FY2023Q2-FY2023Q1-FY2023Q4-FY2022Q3-FY2022Q2-FY2022Q1-FY2022Q4-FY2021Q3-FY2021Q2-FY2021Q1-FY2021
Total Revenue1,304,710$1,261,578$1,111,707$1,264,638$1,283,067$1,172,601$1,240,200$901,862$2,311,065$1,033,925$469,783$320,788$791,078$309,585$265,092$880,634$437,309$276,790$
Cost Of Revenue728,056$1,085,953$650,813$771,225$816,996$883,143$916,058$880,620$1,317,457$841,414$338,620$235,034$265,044$127,308$153,537$78,964$0$0$0$
Gross Profit576,654$175,625$460,894$493,413$466,071$289,458$324,142$21,242$1,570,380$192,511$131,163$(491,018$)249,714$182,277$111,555$(78,964$)880,634$437,309$276,790$
Gross Margin44.20%13.92%41.46%39.02%36.33%24.69%26.14%2.36%67.95%18.62%27.92%(153.07%)31.57%58.88%42.08%100.00%100.00%100.00%
Operating Expenses2,396,652$2,290,954$2,667,153$2,228,375$2,475,078$2,085,629$1,969,087$2,645,656$2,055,530$2,341,719$2,345,047$2,988,178$3,297,096$3,721,902$4,423,653$2,892,651$3,306,301$3,133,739$1,934,318$1,563,925$1,560,089$2,204,315$2,506,808$2,879,650$
Operating Income(1,819,998$)(2,115,329$)(2,206,259$)(1,734,962$)(2,009,007$)(1,796,171$)(1,644,945$)(2,624,414$)(485,150$)(2,149,208$)(2,213,884$)(3,479,196$)(3,047,382$)(3,539,625$)(4,312,098$)(2,971,615$)(2,425,667$)(2,696,430$)(1,657,528$)
Other Income(20,000$)(22,166$)(399,301$)0$(25,204$)(48,153$)0$(48,457$)0$(1,233$)3,000$(89,991$)(4,856,342$)32,996$3,007$(5,148$)(837,911$)(408,842$)(228,954$)
Interest Income51,687$16,565$30,536$57,094$103,640$121,458$166,760$136,043$148,559$155,497$115,797$72,587$33,701$30,964$26,277$5,148$4,825$3,797$3,050$4,345$4,295$26,330$40,495$58,406$
Interest Expenses1,500$3,000$6,800$0$0$360,350$
Income Before Tax(1,788,311$)(2,120,930$)(2,575,024$)(1,677,868$)(1,930,571$)(1,722,866$)(1,478,185$)(2,536,828$)(336,591$)(1,996,444$)(2,098,087$)(3,503,400$)(7,870,023$)(3,475,665$)(4,282,814$)(2,971,615$)(3,258,753$)(3,101,475$)(2,243,782$)(1,599,079$)(1,616,284$)(2,024,058$)(2,493,495$)(2,805,312$)
Tax Expenses6,800$
Income from Continuing Operations(1,788,311$)(2,120,930$)(2,575,024$)(1,677,868$)(1,930,571$)(1,722,866$)(1,478,185$)(2,536,828$)(336,591$)(1,996,444$)(2,098,087$)(3,510,200$)(7,870,023$)(3,475,665$)(4,282,814$)(2,971,615$)(3,258,753$)(3,101,475$)(2,243,782$)(1,599,079$)(1,616,284$)(2,024,058$)(2,493,495$)(2,805,312$)
Income from Discontinued Operations
Consolidated Income(1,788,311$)(2,120,930$)(2,575,024$)(1,677,868$)(1,937,671$)(1,722,866$)(1,478,185$)(2,536,828$)(338,391$)(1,997,944$)(4,202,174$)(3,510,200$)(7,870,023$)(3,475,665$)(8,565,628$)(2,971,615$)(3,258,753$)(3,101,475$)(2,243,782$)(1,599,079$)(1,616,284$)(2,024,058$)(2,493,495$)(2,805,312$)
Net Income(1,788,311$)(2,120,930$)(2,575,024$)(1,677,868$)(1,937,671$)(1,722,866$)(1,478,185$)(2,536,828$)(338,391$)(1,997,944$)(2,101,087$)(3,510,200$)(7,870,023$)(3,475,665$)(4,282,814$)(2,971,615$)(3,258,753$)(3,101,475$)(2,243,782$)(1,599,079$)(1,616,284$)(2,024,058$)(2,493,495$)(2,805,312$)
Profit Margin(137.07%)(168.12%)(231.63%)(132.68%)(151.02%)(146.93%)(119.19%)(281.29%)(14.64%)(193.24%)(447.25%)(1,094.24%)(994.85%)(1,122.69%)(1,615.60%)(370.05%)(709.22%)(810.64%)
Earnings to Minority(2,101,087$)(4,282,814$)
Earnings to Common Shareholders(1,788,311$)(2,120,930$)(2,575,024$)(1,677,868$)(1,937,671$)(1,722,866$)(1,478,185$)(2,536,828$)(338,391$)(1,997,944$)(2,101,087$)(3,510,200$)(7,870,023$)(3,475,665$)(4,282,814$)(2,971,615$)(3,258,753$)(3,101,475$)(2,243,782$)(1,599,079$)(1,616,284$)(2,024,058$)(2,493,495$)(2,805,312$)
Earnings Per Share, Basic(1.21$)(1.94$)(3.64$)(2.71$)(4.05$)(3.58$)(3.71$)(15.24$)(0.10$)(0.60$)(0.91$)(4.06$)(12.27$)(6.14$)(7.73$)(6.17$)0.18$(0.41$)(0.37$)(0.31$)(0.31$)(0.39$)(0.48$)(0.54$)
Earnings Per Share, Diluted(1.21$)(1.94$)(3.64$)(2.71$)(4.05$)(3.58$)(3.71$)(15.24$)(0.10$)(0.60$)(0.91$)(4.06$)(12.27$)(6.14$)(7.73$)(6.17$)0.18$(0.41$)(0.37$)(0.31$)(0.31$)(0.39$)(0.48$)(0.54$)
Average Shares, Basic1,481,2941,095,973706,546620,127478,480480,649398,673166,4103,299,4963,328,1912,300,526865,619641,458566,062553,894481,902-17,785,9347,549,0406,091,3595,220,7075,220,7075,220,7075,220,7075,220,707
Average Shares, Diluted1,481,2941,095,973706,546620,127478,480480,649398,673166,4103,299,4963,328,1912,300,526865,619641,458566,062553,894481,902-17,785,9347,549,0406,091,3595,220,7075,220,7075,220,7075,220,7075,220,707
EBIT(1,788,311$)(2,120,930$)(2,575,024$)(1,677,868$)(1,930,571$)(1,722,866$)(1,478,185$)(2,536,828$)(336,591$)(1,994,944$)(2,095,087$)(3,496,600$)(7,870,023$)(3,475,665$)(4,282,814$)(2,971,615$)(3,258,753$)(3,101,475$)(1,883,432$)(1,599,079$)(1,616,284$)(2,024,058$)(2,493,495$)(2,805,312$)
EBITDA(1,735,559$)(2,068,625$)(2,521,821$)(1,623,289$)(1,875,804$)(1,668,096$)(1,422,954$)(2,481,996$)(283,128$)(1,944,255$)(2,046,038$)(3,447,552$)(7,816,035$)(3,422,325$)(4,233,017$)(2,943,083$)(3,230,105$)(3,074,054$)(1,846,616$)(1,571,098$)(1,589,427$)(1,996,945$)(2,465,263$)(2,775,085$)